About this trial
Wide variability in the antiplatelet effects of aspirin may lead to recurrent thromboembolic events. Several pilot studies have suggested potential benefits of taking aspirin at bedtime rather than in the morning. The primary objective of this study is to examine whether aspirin administration at bedtime versus in the morning provides a superior reduction in the incidence of major adverse cardiovascular events among patients with or without established atherosclerotic cardiovascular disease, who are already taking aspirin.
Eligibility criteria
Qualifiers
Age >=18 years
Current chronic treatment with aspirin (as recorded in the Danish National Prescription Registry and confirmed by the participant via questionnaire)
Signed informed consent
Disqualifiers
There are no exclusion criteria for this trial
Trial design
Treatments tested in this trial
- Aspirin
Treatment groups
Sponsors and collaborators
Tor Biering-Sørensen
Lead sponsor
Herlev and Gentofte Hospital
Sponsor institution